Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial comparing continuous versus intermittent zanubrutinib in older patients with previously untreated mantle cell lymphom…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating pacritinib in combination with a BTK inhibitor for relapsed or refractory mantle cell lymphoma is curren…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial to compare glofitamab as a single agent against investigator's choice in relapsed/refractory mantle cell lymphoma is …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL [Phase 2]
Phase 2 open-label randomized trial evaluating the combination of pirtobrutinib and Brexucabtagene Autoleucel in relapsed/refractory mantle …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating memory-enriched T cells following stem cell transplantation for recurrent B-cell non-Hodgkin lymphomas; the study i…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma [Phase 3]
A Phase III randomized trial evaluating orelabrutinib plus R-CHOP versus R-CHOP alone in treatment-naïve mantle cell lymphoma has completed.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating the combination of glofitamab and lenalidomide in patients with mantle cell lymphoma.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy [Phase 2]
Phase 2 trial evaluating the combination of Sonrotoclax and Zanubrutinib in relapsed/refractory Mantle Cell Lymphoma patients who are planne…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial update comparing three chemotherapy regimens for newly diagnosed mantle cell lymphoma, currently active/not recruit…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating ibrutinib in untreated high-risk smoldering mantle cell lymphoma; the study is currently active but n…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies [NA]
This clinical trial update describes an evaluation of MTM-H-001 injection in adults with relapsed or refractory B-cell lymphomas, with the s…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating nemtabrutinib in combination with rituximab for mantle cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) [Phase 2]
This clinical trial update reports on a Phase 2 study of Zilovertamab Vedotin (MK-2140) as monotherapy and in combination for aggressive and…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating glofitamab in combination with lenalidomide is underway for high-risk patients with relapsed or refracto…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the combination of ibrutinib, a CD20 antibody, and venetoclax in patients wi…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 study evaluating feasibility and safety of collecting autologous hematopoietic stem cells and combining them with CAR T-cell thera…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…